Mallinckrodt, a specialty pharmaceutical company, will build out a new campus in the Somerset financial center in Bedminster, New Jersey for its specialty brands organizations. Mallinckrodt will invest more than $80 million in New Jersey. The Bedminster campus will consolidate operations for its specialty brands groups, co-locating more than 400 commercial and science employees focused on marketed and development products in its autoimmune and rare diseases and hospital businesses. The company anticipates that the approximately 400 employees will occupy the new space in the first quarter of 2017.

The investment is intended to help consolidate operations after a series of acquisition over the last 18 months that resulted in Mallinckrodt having commercial and development operations spread across more than a dozen US sites.

The company is also continuing its investment in St. Louis, Missouri, having recently begun the next phase of construction at its downtown St. Louis manufacturing facility. Recent investment includes the commitment of more than $8 million for expansion of its downtown St. Louis manufacturing facility as well as a $12-million site addition opened in mid-2015 to increase manufacturing efficiency. These are part of a more than $140 million in recent investments in capital projects and related expenses the company has invested in offices and plant locations that house Mallinckrodt’s legacy businesses and key administrative functions in the area.

Source: Mallinckrodt